AN ESTABLISHED FIRST-LINE STANDARD OF CARE
WITH A SURVIVAL BENEFIT1,6
AN ESTABLISHED FIRST-LINE STANDARD OF CARE WITH A SURVIVAL BENEFIT1,6

ABRAXANE (125 mg/m2 QW3/4) + gemcitabine significantly increased median OS vs gemcitabine alone ABRAXANE (125 mg/m2 QW3/4)
+ gemcitabine significantly increased
median OS vs gemcitabine alone
Median overall survival: ABRAXANE + gemcitabine vs gemictabine Median overall survival: ABRAXANE + gemcitabine vs gemictabine
  • aStratified using Cox proportional hazard model.
  • bBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
  • aStratified using Cox proportional hazard model.
  • bBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
  • ORR (Overall Response Rates)

    RESPONSE MATTERS:
    ORR ASSESSED BY INDEPENDENT REVIEW

    ABRAXANE (125 mg/m2 QW3/4) + gemcitabine more than tripled ORR vs gemcitabine alone
    Overall response rates: ABRAXANE + gemcitabine vs gemcitabine Overall response rates: ABRAXANE + gemcitabine vs gemcitabine
    CLOSE THE TAB
  • PFS (Progression-Free Survival)

    ABRAXANE + GEMCITABINE
    SIGNIFICANTLY IMPROVED PFSa

    49% increase in median PFS with ABRAXANE (125 mg/m2 QW3/4) + gemcitabine
    compared with gemcitabine alone1
    49% increase in median PFS with ABRAXANE (125 mg/m2 QW3/4)
    + gemcitabine compared with gemcitabine alone1
    Progression-free survival: ABRAXANE + gemcitabine vs gemcitabine Progression-free survival: ABRAXANE + gemcitabine vs gemcitabine
    • aBased on independent radiological reviewer assessment.
    • bStratified using Cox proportional hazard model.
    • cBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL